N/A N=7 Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
Adrenal Insufficiency
Primary: Number of Participants With Adrenal Insufficiency — 7 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Phase 3 N=95 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Phase 3 N=62 Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia (CAH)
Primary: Adult Height Relative to General Population — -0.34; -0.6 Standard Deviation Score (SDS) units
Phase 3 N=24 Treatment of Adrenal Insufficiency in Children
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
N/A N=30 Evaluation of Etomidate on Adrenal Function in Trauma Patients
Adrenal Insufficiency
Primary: Cortisol Levels Pre and Post Rapid Sequence Induction and Cortisol Stimulation Test
Phase 1 N=16 A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)
HIV-1 Infection
Primary: Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) of Doravirine — 53.9; 54.6 µM*hr
Phase 2 N=14 Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Phase 3 N=18 Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Adrenal Tumors
Primary: Increase in Catecholamine
N/A N=43 The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis
Adult Growth Hormone Deficiency · Hypothalamic-pituitary Disorders
Primary: Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD). — 0.9; 0.6; 0.7 ng/mL
Phase 3 N=64 Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Adrenal Insufficiency
Primary: Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A — 3962.0; 4879.6 hour*nanomole…
Phase 3 N=40 Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Viral Response 12 Weeks After Completing Study Therapy (SVR12) — 90.0; 100.0 Percentage of participants
Phase 1 N=157 Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3
Healthy
Primary: Serum 25-hydroxyvitamin D — 26.7; 22.4 ng/mL — p=0.003
Phase 1 N=24 Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)
Renal Insufficiency · Renal Impairment
Primary: Geometric Least Squares Mean Area Under the Plasma Drug Concentration-time Curve From Time Zero to Infinity (AUC0-∞) Following a Single IV Dose of Sugammadex — 339; 151…
N/A N=28 Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr